• S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients

  • Feb 27 2021
  • Length: 24 mins
  • Podcast

S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients

Listen for free

View show details

  • Summary

  • Visit http://morningcommutepodcast.com/SGLT2inhibitors2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss clinical trial data that look at new directions for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, particularly how they benefit patients with chronic kidney disease (CKD).
    Show More Show Less
Show More Show Less
activate_samplebutton_t1

What listeners say about S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.